I think you might be confusing nwbo with one of those preclinical companies you talk about all the time because your prior post was 100% inaccurate as far as nwbo is concerned.
If you believe helping 100K nGBM patients annually isn't worth addressing then that's your prerogative. Glioblastoma happens to be one of the most heterogeneous cancers. If DCVax can kill those tumors then others less complex should be achievable.